Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Hims & Hers Health (HIMS) and Tyra Bioscience (TYRA)

Tipranks - Tipranks - Sat Mar 21, 7:02AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viatris (VTRS), Hims & Hers Health (HIMS) and Tyra Bioscience (TYRA).

Claim 70% Off TipRanks Premium

Viatris (VTRS)

Truist Financial analyst Les Sulewski maintained a Buy rating on Viatris today. The company’s shares closed last Thursday at $13.50, close to its 52-week high of $13.55.

According to TipRanks.com, Sulewski is a 3-star analyst with an average return of 2.1% and a 43.1% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Bausch Health Companies, and Amneal Pharmaceuticals. ;'>

Currently, the analyst consensus on Viatris is a Moderate Buy with an average price target of $14.80.

See Insiders’ Hot Stocks on TipRanks >>

Hims & Hers Health (HIMS)

Truist Financial analyst Jailendra Singh maintained a Hold rating on Hims & Hers Health today. The company’s shares closed last Thursday at $24.16.

According to TipRanks.com, Singh has 0 stars on 0-5 stars ranking scale with an average return of -16.4% and a 29.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Revolution Medicines. ;'>

Currently, the analyst consensus on Hims & Hers Health is a Moderate Buy with an average price target of $26.00, representing a 13.6% upside. In a report issued on March 9, Citi also upgraded the stock to Hold with a $24.00 price target.

Tyra Bioscience (TYRA)

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Tyra Bioscience today and set a price target of $56.00. The company’s shares closed last Thursday at $38.18.

According to TipRanks.com, Bratzel is a 5-star analyst with an average return of 47.3% and a 58.7% success rate. Bratzel covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Abivax SA Sponsored ADR. ;'>

Currently, the analyst consensus on Tyra Bioscience is a Strong Buy with an average price target of $50.71, which is a 34.4% upside from current levels. In a report issued on March 10, TD Cowen also maintained a Buy rating on the stock.

Read More on VTRS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).